Suscribirse

Transient Hyponatremia During Hospitalization for Acute Heart Failure - 22/05/16

Doi : 10.1016/j.amjmed.2016.01.016 
Frederik H. Verbrugge, MD, PhD a, b, c, Justin L. Grodin, MD, MPH a, Wilfried Mullens, MD, PhD b, d, David O. Taylor, MD a, Randall C. Starling, MD, MPH a, W.H. Wilson Tang, MD a,
a Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Ohio 
b Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium 
c Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium 
d Biomedical Research Institute, Department of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium 

Requests for reprints should be addressed to W. H. Wilson Tang, MD, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Desk J3-4, Cleveland, OH 44195.Department of Cardiovascular MedicineHeart and Vascular InstituteCleveland Clinic9500 Euclid AveDesk J3-4ClevelandOH44195

Abstract

Objective

The objective was to study whether the temporal pattern of transient hyponatremia development in acute heart failure might provide insight into its pathophysiology and prognostic relevance.

Methods

A post hoc analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) and Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE AHF) studies was performed (n = 716). Patients were stratified according to the temporal pattern of hyponatremia development: (1) no hyponatremia, (2) persistent hyponatremia, (3) decompensation hyponatremia disappearing with decongestive treatment, and (4) treatment-induced hyponatremia.

Results

Transient decompensation versus no hyponatremia was associated with significantly elevated blood urea nitrogen/creatinine ratio (P < .001), plasma renin activity (P < .001), and plasma aldosterone levels (P < .001) at baseline. Disease severity characteristics of such patients were intermediate between no and persistent hyponatremia. In contrast, patients with treatment-induced versus no hyponatremia had similar baseline characteristics and comparable natriuretic peptide levels, and both groups had little neurohumoral activation at baseline. Diuretic efficacy, defined as net fluid balance (milliliters) per 40 mg furosemide-equivalent dose administered, was lower in patients with persistent or treatment-induced hyponatremia versus decompensation hyponatremia or no hyponatremia, respectively. The former versus latter groups also had more pronounced neurohumoral activation with decongestive treatment. The risk for all-cause mortality (hazard ratio, 2.50; 95% confidence interval, 1.50-4.19; P < .001) and death or heart failure readmission (hazard ratio, 2.18; 95% confidence interval, 1.60-2.97; P < .001) was significantly elevated in patients with persistent versus no hyponatremia, with the risk of decompensation and treatment hyponatremia situated in between.

Conclusions

Transient hyponatremia is prognostically relevant, but it has a heterogeneous cause according to its temporal pattern of development.

El texto completo de este artículo está disponible en PDF.

Keywords : Diuretics, Heart failure, Prognosis, Sodium


Esquema


 Funding: FHV is supported by a PhD fellowship of the Research Foundation–Flanders (FWO, 11L8214N). FHV and WM are researchers for the Limburg Clinical Research Program UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk, Hasselt University, Ziekenhuis Oost-Limburg, and Jessa Hospital. WHWT is supported by the National Institutes of Health grant R01HL103931.
 Conflict of Interest: None.
 Authorship: All authors had access to the data and played a role in writing this manuscript.


© 2016  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 129 - N° 6

P. 620-627 - juin 2016 Regresar al número
Artículo precedente Artículo precedente
  • Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry
  • Dalene M. Bott-Kitslaar, Rayya A. Saadiq, Robert D. McBane, Charles L. Loprinzi, Aneel A. Ashrani, Teresa R. Ransone, Alissa A. Wolfgram, Michelle M. Berentsen, Waldemar E. Wysokinski
| Artículo siguiente Artículo siguiente
  • Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding
  • Joanna M. Peloquin, Siamak M. Seraj, Lindsay Y. King, Emily J. Campbell, Ashwin N. Ananthakrishnan, James M. Richter

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.